DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP

被引:29
作者
Gault, VA [1 ]
Irwin, N
Harriott, P
Flatt, PR
O'Harte, FPM
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
[2] Queens Univ Belfast, Ctr Peptide & Prot Engn, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland
关键词
dipeptidylpeptidase IV; glucose-dependent insulinotropic polypeptide; GIP analogue; insulin secretion;
D O I
10.1016/S1065-6995(02)00255-X
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Structure-function studies suggest that preservation of the N-terminus and secondary structure of glucose-dependent insulinotropic polypeptide (GIP) is important for biological activity. Therefore, a novel di-substituted analogue of GIP, (Ser(2)-Asp(13))GIP, containing a negatively charged Asp residue in place of an Ala in position 13, seas synthesised and evaluated for in vitro biological activity. Incubation with dipeptidyl peptidase IV (DPP IV) showed the half-lives of GIP and (Ser(2)-Asp(13))GIP to be 2.3 and >4 h, respectively. Insulin releasing studies in clonal pancreatic BRIN-BD11 cells demonstrated that (Ser(2)-Asp(13))GIP (10(-12) to 10(-7) mol/l) was significantly less potent (60-90%; P<0.05 to P<0.001) than native GIP. The peptide failed to display antagonistic properties as it did not significantly alter insulin secretion when incubated in the presence of GIP (10(-7) mol/l). These results demonstrate that despite increased resistance to DPP IV, substituting Ala in position 13 with a negatively charged Asp, thus producing the di-substituted analogue (Ser(2)-Asp(13))GIP, significantly reduces biological activity, most likely due to modifications within the secondary structure. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 17 条
[1]  
BUCHAN MT, 1978, HISTOCHEMISTRY, V43, P249
[2]   The entero-insular axis in type 2 diabetes - incretins as therapeutic agents [J].
Creutzfeldt, W .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 :S288-S303
[3]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[4]   Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs [J].
Deacon, CF ;
Danielson, P ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
DIABETES, 2001, 50 (07) :1588-1597
[5]  
FLATT PR, 1981, DIABETOLOGIA, V20, P573
[6]  
Flatt PR, 2001, DIABETOLOGIA, V44, pA195
[7]   Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide [J].
Gault, VA ;
O'Harte, FPM ;
Harriott, P ;
Flatt, PR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (05) :1420-1426
[8]  
Gault VA, 2001, DIABETOLOGIA, V44, pA195
[9]   Dipeptidyl peptidase IV-resistant [D-Ala2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats [J].
Hinke, SA ;
Gelling, RW ;
Pederson, RA ;
Manhart, S ;
Nian, C ;
Demuth, HU ;
McIntosh, CHS .
DIABETES, 2002, 51 (03) :652-661
[10]   Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP) [J].
Hinke, SA ;
Manhart, S ;
Pamir, N ;
Demuth, HU ;
Gelling, RW ;
Pederson, RA ;
McIntosh, CHS .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2001, 1547 (01) :143-155